Abarceo Pharma Ab
Abarceo is a preclinical stage company. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
10
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 5 verified contacts at Abarceo Pharma Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- RJ
Ruchi Jain
Principal Scientist · Science
EmailPhone - CN
Cornelia Nilsson
Research Assistant · Research & Development
EmailPhone - AG
Annie George Chandy
Board Member · General Business & Management
EmailPhone
Showing 3 of 5 verified contacts
Top roles at Abarceo Pharma Ab
3 distinct titles indexed · top 3 shown.
- 1board member
- 1principal scientist
- 1research assistant
Sign up to unlock all 5 contacts at Abarceo Pharma Ab
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Abarceo Pharma Ab
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.